Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly EBT Margin of 135.29% for Q1 2026, down 2738.0% year-over-year from 5.13% in Q1 2025, and down 130.46% quarter-over-quarter from 58.71% in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported EBT Margin for 11 consecutive years, with 135.29% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 2738.0% year-over-year to 135.29%; the TTM figure through Mar 2026 stood at 89.48% (up 249.0% YoY), while the FY2025 annual figure was 83.95%, up 1658.0% from the prior year.
- EBT Margin fell to 135.29% in Q1 2026 per RARE's latest filing, from 58.71% in the prior quarter.
- Across five years, EBT Margin topped out at 58.71% in Q4 2025 and bottomed at 263.3% in Q3 2022.
- Historically, EBT Margin has averaged 132.46% across 5 years, with a median of 135.29% in 2026.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 54750 bps — and 2023, when it surged 10114 bps.
- Ultragenyx Pharmaceutical's EBT Margin stood at 148.32% in 2022, then surged by 32 bps to 100.22% in 2023, then rose by 22 bps to 78.24% in 2024, then rose by 25 bps to 58.71% in 2025, then tumbled by 130 bps to 135.29% in 2026.
- Business Quant data shows RARE's EBT Margin at 135.29% in Q1 2026, 58.71% in Q4 2025, and 112.26% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | -42.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.52% |
| Mar 31, 2026 | -135.29% |
| Dec 31, 2025 | -61.60% |
| Sep 30, 2025 | -112.26% |
| Jun 30, 2025 | -68.26% |
| Mar 31, 2025 | -107.91% |
| Dec 31, 2024 | -80.67% |
| Sep 30, 2024 | -95.50% |
| Jun 30, 2024 | -88.92% |
| Mar 31, 2024 | -156.41% |
| Dec 31, 2023 | -100.22% |
| Sep 30, 2023 | -162.16% |
| Jun 30, 2023 | -146.89% |
| Mar 31, 2023 | -162.67% |
| Dec 31, 2022 | -149.95% |
| Sep 30, 2022 | -263.30% |
| Jun 30, 2022 | -176.69% |
| Mar 31, 2022 | -189.86% |
| Dec 31, 2021 | -149.63% |
| Sep 30, 2021 | -89.18% |